Understanding Hypersensitivity Pneumonitis
Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease triggered by repeated inhalation of organic or inorganic antigens in genetically susceptible individuals, requiring systematic evaluation through exposure history, high-resolution CT imaging, and multidisciplinary discussion to establish diagnosis. 1, 2
Disease Definition and Classification
HP represents a complex immunological reaction involving the lung parenchyma, alveoli, terminal bronchioles, and alveolar interstitium following sensitization to inhaled antigens 3. The disease has evolved from outdated time-based classifications (acute/subacute/chronic) to a more clinically relevant framework.
The current classification divides HP into two phenotypes based on the presence or absence of fibrosis on high-resolution CT (HRCT):
- Nonfibrotic HP - purely inflammatory disease
- Fibrotic HP - disease with radiological and/or histopathological evidence of fibrosis 1, 2
This distinction is critical because fibrosis presence provides important prognostic information and fundamentally alters treatment approaches 2.
Causative Agents and Epidemiology
The inciting antigens (IAs) include:
- Organic dusts: fungal spores, bacterial proteins, avian proteins (most common)
- Occupational exposures: agricultural dusts, industrial chemicals
- Home exposures: mold, birds, hot tubs, humidifiers
- Medications: less common but increasingly recognized 3, 4
A critical pitfall: the inciting antigen often goes unrecognized or exposure has ceased before diagnosis 2. The IA should be classified as:
- Identified (known exposure with clear temporal relationship)
- Indeterminate (possible exposure but uncertain)
- Unidentified (no clear exposure identified) 2
Prevalence ranges from 1-2 cases per 100,000 annually in North America and Europe, with most patients presenting after age 40. Fibrotic HP represents up to 10% of interstitial lung disease cases 2, 5.
Clinical Presentation
Nonfibrotic HP
- Subacute respiratory symptoms: dyspnea, cough (typically nonproductive)
- Systemic symptoms: fever, chills, malaise, weight loss
- Symptoms often improve away from exposure and worsen upon re-exposure
- Physical exam: inspiratory crackles, possible squeaks 6
Fibrotic HP
- Insidious onset of progressive dyspnea and cough
- Symptoms persist regardless of exposure cessation
- May lack systemic symptoms
- Physical exam: inspiratory crackles, clubbing in advanced cases
- Often misdiagnosed as idiopathic pulmonary fibrosis (IPF) 2, 5
Diagnostic Workup
Step 1: Exposure Assessment
Take a thorough environmental and occupational history to identify potential exposures 1. Focus on:
- Home environment (water damage, humidifiers, birds, feather bedding)
- Occupational exposures (farming, metalworking, woodworking)
- Hobbies (bird keeping, hot tubs)
- Temporal relationship between exposure and symptoms 2
Step 2: High-Resolution CT Imaging
HRCT is essential and should be obtained early in the diagnostic algorithm 1, 2.
Nonfibrotic HP CT Patterns:
Typical findings:
- Profuse poorly defined centrilobular ground-glass nodules affecting all lung zones
- Inspiratory mosaic attenuation with "three-density sign"
- Mosaic attenuation and air-trapping associated with centrilobular nodules 2
Compatible findings:
- Centrilobular nodules that are not profuse or diffuse
- Patchy or diffuse ground-glass opacity
- Mosaic attenuation without centrilobular nodules 2
Fibrotic HP CT Patterns:
Typical findings:
- Fibrosis (reticular abnormality, traction bronchiectasis/bronchiolectasis, honeycombing) with:
Compatible findings:
- Fibrosis with some but not all typical features
- May show upper or mid-lung predominance 2
Indeterminate findings:
- CT signs of fibrosis without other features suggestive of HP 2
Step 3: Bronchoalveolar Lavage (BAL)
For nonfibrotic HP: BAL with lymphocyte cellular analysis is recommended 1.
For fibrotic HP: BAL is suggested but not mandatory 1, 2.
Key BAL findings:
- Lymphocytosis ≥20% supports HP diagnosis (higher thresholds like ≥30-40% increase specificity)
- In nonfibrotic HP with unidentified antigen, absence of lymphocytosis substantially reduces diagnostic confidence
- In fibrotic HP, absence of lymphocytosis does not rule out disease 2
Critical caveat: BAL lymphocytosis alone does not confirm HP and must be interpreted with clinical context, smoking history, and imaging findings 2.
Step 4: Serum IgG Testing
Serum IgG testing targeting potential HP antigens is suggested for nonfibrotic HP 1. However, positive IgG indicates exposure and sensitization, not disease. Negative IgG does not exclude HP, especially if comprehensive antigen panels are unavailable 6.
Step 5: Histopathology (When Needed)
Transbronchial forceps biopsy is suggested for nonfibrotic HP 1.
For fibrotic HP, transbronchial cryobiopsy or surgical lung biopsy should be considered when diagnosis remains uncertain after clinical, radiological, and BAL evaluation 1, 2.
Histopathologic patterns:
Typical HP:
- Cellular and/or fibrosing interstitial pneumonia with bronchiolocentric accentuation
- Poorly formed non-necrotizing granulomas with or without giant cells
- Peribronchiolar metaplasia
- Small foci of organizing pneumonia 2
Compatible HP:
- Some but not all typical features
- May show NSIP or UIP-like patterns in fibrotic HP 2
Important pitfall: Isolated findings like granulomas or organizing pneumonia are not specific for HP and require multidisciplinary discussion 2.
Step 6: Multidisciplinary Discussion (MDD)
All diagnostic information must be integrated through MDD to establish diagnostic confidence 1, 2. The MDD assigns confidence levels:
- HP ≥90%: Confident diagnosis
- High confidence ~70-89%: Provisional diagnosis
- Low confidence ~51-69%: Provisional diagnosis with uncertainty
- Unlikely ≤50%: Consider alternative diagnoses 2
Diagnostic Algorithm
For suspected nonfibrotic HP:
- Assess exposure (identified/indeterminate/unidentified)
- Obtain HRCT
- If HRCT typical + identified exposure → confident diagnosis
- If HRCT compatible or exposure indeterminate → obtain BAL
- If BAL shows lymphocytosis → high confidence diagnosis
- If BAL negative and exposure unidentified → consider transbronchial biopsy
- MDD to finalize diagnosis 2
For suspected fibrotic HP:
- Assess exposure
- Obtain HRCT
- If HRCT typical + identified exposure → high confidence diagnosis
- If HRCT compatible or indeterminate → consider BAL and/or biopsy
- Transbronchial cryobiopsy or surgical lung biopsy if diagnosis remains uncertain
- MDD to finalize diagnosis and distinguish from IPF 2
Critical distinction from IPF: Fibrotic HP often mimics IPF. Consider HP in patients with:
- Mid-to-upper lung predominance of fibrosis
- Relative subpleural sparing
- Mosaic attenuation or air-trapping
- Any identifiable exposure history
- Age <60 years, female sex, or non-smoker 2, 5
Treatment Approaches
Antigen Avoidance
Complete antigen avoidance is the cornerstone of treatment and should be implemented immediately upon diagnosis 5, 4. This may require:
- Environmental remediation (mold removal, HEPA filtration)
- Occupational changes
- Removal of birds or feather products
- Discontinuation of causative medications
Caveat: Complete avoidance may be impossible if antigen is unidentified or requires major lifestyle changes 3.
Pharmacologic Management
For nonfibrotic HP:
- Systemic corticosteroids (prednisone 0.5-1 mg/kg/day, tapered over 3-6 months) for symptomatic patients
- Monitor for response and taper based on clinical improvement 5, 4
For fibrotic HP:
- Immunosuppression (corticosteroids with or without steroid-sparing agents like azathioprine or mycophenolate) is the traditional first-line approach, particularly when inflammatory features predominate 5
- Antifibrotic therapy (nintedanib or pirfenidone) should be considered as second-line therapy for progressive fibrotic HP despite immunosuppression, or as first-line when fibrosis predominates over inflammation 5
- No direct comparison exists between immunosuppression and antifibrotic therapy; choice depends on:
- Extent of inflammation vs. fibrosis on imaging
- Presence of BAL lymphocytosis (favors immunosuppression)
- Histopathologic pattern (UIP-like pattern may favor antifibrotics)
- Disease progression despite antigen avoidance 5
Monitoring
- Serial pulmonary function tests (FVC, DLCO) every 3-6 months
- Repeat HRCT at 6-12 months or if clinical deterioration
- Reassess exposure and antigen avoidance measures
- Consider lung transplantation evaluation for progressive fibrotic disease 5, 8
Prognosis
Prognosis depends primarily on the presence and extent of fibrosis 2. Nonfibrotic HP generally has favorable outcomes with antigen avoidance. Fibrotic HP, particularly with UIP-like pattern or extensive honeycombing, carries a prognosis similar to IPF with median survival of 3-5 years without treatment 5, 9.